AB Science S.A (AB) Fair Value & Analysis
Healthcare · FR · Market cap €67.3M
Fair value as of: Jun 24, 2026
From 3 valuation models · updated 5 days ago
Share price −6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range €0.8226 – €1.57 · fair‑value band €0.1300 – €0.1500 · the €0.8680 price screens above the €0.1400 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AB Science S.A (AB) currently trades at €0.8680, while our model-based Fair Value estimate is €0.1400 — implying the stock looks roughly 83.9% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at €1.2M. Revenue grew 28.7% year over year. The balance sheet holds a net cash position of €5.9M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AB Science S.A reported revenue of €1.2M in FY2025 versus €1.6M in FY2021, a compound −7.5%/yr. Reported net income was −€1.6M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,863 | ₹1,039 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AB Science S.A (AB) undervalued?
What is the fair value of AB?
What is the quality score of AB?
What is the revenue of AB Science S.A (AB)?
What is the net profit margin of AB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.